Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom

Takeaway: Capital markets businesses are starting to turn down signified by JPM and this cyclical stock "looks" cheap only on trailing results.

  "When you expect things to happen...strangely enough they happen." - J.P. Morgan


Most of the JP Morgan Investor Day this week was backward looking with the bulk of the presentation spent on an annual recap of the Corporate and Investment Bank (CIB) in 2015. The most relevant data however was the simple reference to running 1Q16 activity trends which are down -25% year-over-year. While there was no deconstruction of the drivers of this slack, our data suggests a 30-40% decline in underwriting, with a negative 5-10% start for M&A (described as "holding well" by the CIB Head). JP Morgan matters with top 3 share across the board in capital markets.


Global M&A announcements have started down mid-single digits in January and February with U.S. announcements more volatile having putting up a solid January, up 42% year-over-year, with a forming -20% decline for February. The across cycle look at merger activity shows the new 2015 zenith having taken out the '07 highs, with even the slight decline to start 2016 looking like a massive slough off. We think this slow start to the year turns into an intermediate term trend and that the M&A advisory group will be comping negatively throughout 2016. The main culprit at his juncture is the backup of corporate credit costs which are maintaining levels, some 100 basis points higher across Moody's most widely referenced indices. Historically, M&A has comped down by -20% with a 100 basis point back up in credit, which implies an M&A market just starting a more substantial decline.


On the asset management side, headwinds persist with a stubbornly high U.S. dollar and risk aversion for EM assets. The Chinese Yuan devaluation now appears to be driving the depreciation in the MSCI Emerging Markets index and with the outlook for the Chinese currency weak at best considering capital flight and slowing growth, the situation warrants caution.


Like most cyclical stocks, Lazard "looks" cheapest at market tops as its earning downturn is just getting started versus at market bottoms when the company is underearning and shares "look" expensive (but they are actually great early cycle longs). We have earnings flat at $2.80 for 2016 and 2017 which we capitalize at 8-9x for a fair value of $25. However in a 1 Emerging Market type downcycle, Lazard asset management with ~50% of its asset-under-managments in EM credit and equity will cause LAZ stock to overcorrect and spit off more downside (substituting current day China for Thailand in '97 in running out of FX reserves to support its currency and plugging in Venezuela or the Ukranine for Russia's '98 default). 


The update on 1Q16 trends from JP Morgan matters as a top 3 player in most business lines in capital markets:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - Chart 13   JPM share


The flattish start to global M&A for 2016 looks like a massive decline being that M&A activity put in its high water mark in the middle of last year. In addition to "comping the comp" as we move further into the year, M&A activity will be battling volatility and the fundamental change in corporate credit costs:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart revised

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 15   global announcements


U.S. activity had a solid January but is putting in a slump in February. Historically, U.S. activity is 60% of global announcements.:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 16   US announcements


 The inflection in corporate credit costs hasn't normalized which pressures funding costs and M&A synergies:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 6   credit inflection


 And the year-over-year change in credit costs (inverted - left scale) does drive the growth or decay of M&A volume:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 7   yoy credit


 Every 100 bps of credit cost expansion has historically depressed M&A by -20%. Currently, the four quarter moving average of corporate credit has backed up by 25 bps, essentially confirming the -4-6% start for global M&A:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 8   scatter plot


 Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 9   4 quarter moving average


And although the firm will have a strong 1Q16 report (the company advised on 6 of the 10 largest deals in 2015 but only closed 1 of them during the year), the stock discounts the revenue environment 3 quarters ahead of time:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 2  discounting


Lazard stock is a great early cycle performer but kicks off decidedly negative returns at the end of cycle:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 1   Early Cycle


 The rising volatility environment is not good for cyclicals as the VIX (inverted right scale) historically pushes the stock down:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 5   VIX stock


 On the asset management side, non-local Lazard Asset Management strategies regress closely to EM markets which means their exposure is understated:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 10   non local linear


 And the debasement of the Chinese Yuan (inverted scale) is down driving EM market returns:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 11   chinese yuan v mxef


 The last EM down cycle created redemption rates of between ~ negative 2-5% in 2002-2004 versus the +2% organic growth in LAZ asset management to finish 2016:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - chart 12   down cycle


We hear alot from investors that the stock "is as cheap as its ever been" however like a true cyclical, the best time to buy shares is when it is underearning early in the cycle (note 20x LAZ earnings multiple in 2009-2010). LAZ is overearning currently coming out of the M&A boom of 2014-2015:

Lazard (LAZ) | Cheap at the Top...Expensive at the Bottom - Valuation 



LAZ - Hiring in Restructuring, Chairman Bullish From Davos

LAZ - Value Trap - Best Ideas BlackBook

LAZ - As Good As It Gets


Please let us know of questions,


Jonathan Casteleyn, CFA, CMT 




Joshua Steiner, CFA

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more

Capital Brief: 5 Things to Watch Right Now In Washington

Here's a quick look at some key issues investors should keep an eye on from Hedgeye's JT Taylor and our team of Washington Policy analysts in D.C.

read more

Premium insight

[UNLOCKED] Today's Daily Trading Ranges

“If I could only have one thing of the many things we have it would be my daily ranges." Hedgeye CEO Keith McCullough said recently.

read more

We'll Say It Again: Leave Your Politics Out of Your Portfolio

If your politics dictates your portfolio positioning, the Democrats and #NeverTrump crowd out there have had a hell of a week.

read more

Cartoon of the Day: 'Biggest Tax Cut Ever'

President Donald Trump's economic team unveiled what he called last week, "the biggest tax cut we’ve ever had.” Before you get too excited about that hang on a sec. "Trump Tax Reform ain’t gettin’ done anytime soon," Hedgeye CEO Keith McCullough wrote in today's Early Look.

read more